Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)

Trial Profile

Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Aliskiren (Primary) ; Candesartan cilexetil
  • Indications Kidney disorders
  • Focus Therapeutic Use
  • Acronyms RASQAL
  • Most Recent Events

    • 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 10 Apr 2013 Planned end date changed from 12 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 10 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01827202).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top